Phenylethanolamine N-methyltransferase (PNMT) is the final enzyme of catecholamine synthesis: a cytosolic methyltransferase that transfers a methyl group from S-adenosylmethionine to norepinephrine, producing epinephrine. It sits in the adrenal medulla's chromaffin cells — induced by glucocorticoids from the cortex's portal drainage, a beautiful anatomical coupling of the stress axis to its transmitter — and in brainstem adrenergic neurons. Its substrate specificity accepts phenylethanolamines, which is why it also N-methylates synthetic substrates: the enzyme behind adrenaline, literally the endocrine medulla's signature step.
A single-domain SAM-dependent methyltransferase: the SAM cofactor's sulfonium methyl is transferred to the amine — an SN2 handoff that structure and mechanism both support.
The catalytic histidine/aspartate pair deprotonates the amine for attack — a mechanism shared with nicotinamide N-methyltransferase's clan.
Crystal structures with adrenaline and inhibitors (SKF-29661 era) mapped the pocket's phenyl-acceptor geometry.
Function
Epinephrine supply: the adrenal medulla's ~85% epinephrine phenotype depends on PNMT — the last and committing step of the adrenaline pathway (tyrosine → DOPA → dopamine → norepinephrine → epinephrine).
Brain adrenergic phenotype: PNMT-expressing neurons of the C1–C3 cell groups define the epinephrine (adrenergic) neurotransmitter phenotype versus noradrenergic, see neuron typing.
Developmental timing: PNMT appears in late gestation — the fetal adrenal's epinephrine capacity comes last, after the glucocorticoid induction machinery matures.
Regulation
Glucocorticoid induction: the corticomedullary portal system delivers cortex effluent at ~100× systemic cortisol to the medulla — the anatomical explanation for the medulla's PNMT; see cortisol.
Transcriptional induction also by neural (splanchnic) activity and hypoxia; Egr1/Sp1 regulatory elements in the promoter.
Product feedback and substrate availability (from norepinephrine synthesis) set steady-state flux.
Interactions
Upstream enzymes: tyrosine hydroxylase and dopamine β-hydroxylase — the pathway's rate-limiting and antepenultimate steps; PNMT completes the set.
With SAM metabolism: PNMT draws on the methionine cycle's methyl donor — one-carbon metabolism's link to catecholamines.
With pharmacology: PNMT inhibitors studied as antihypertensives historically; epinephrine's synthesis is measured in pheochromocytoma workups by the pathway's metanephrines.
Clinical Relevance
Biomarker axis: PNMT underlies the epinephrine/metanephrine fractions that localise pheochromocytoma and paraganglioma; adrenal vs extra-adrenal tumors differ by PNMT expression.
Cardiovascular genetics: PNMT promoter variants associate with blood-pressure and stress-response phenotypes; exercise-induced epinephrine responses vary by genotype.
Neurologic research: adrenergic-neuron PNMT maps the CNS epinephrine system — central stress circuitry's marker enzyme.